Home › Markets › Health Care › ALKS

Alkermes plc (ALKS)

ALKS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$39.73
-1.32% on the day
Market cap
$6.7B
Mid cap
Revenue · 2025
$1.5B
-5.2% on 2024
Net income · 2025
$241.7M
16.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerALKS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIreland
IPO year1991
SEC CIK0001520262
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$1.5B
Net income$241.7M
Operating income$254.0M
Net margin16.4%
Operating margin17.2%
Revenue growth-5.2%
Cash$388.6M
Total assets$2.5B
P/E (computed)27.6×
P/S (computed)4.5×

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-07-28
Latest current report8-K2026-09-21
Latest proxyDEFA14A2026-05-13

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.1%
1 month-14.5%
3 months-24.2%
Year to date+40.6%
1 year+22.3%
From 52-week high-28.7%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PRAXPraxis Precision Medicines Inc.$243.34-3.20%$6.8B
AMRXAmneal Pharmaceuticals Inc.$19.57-2.30%$6.8B
IONSIonis Pharmaceuticals Inc.$42.38-2.95%$7.0B
SYRESpyre Therapeutics Inc.$80.45-6.34%$7.1B
KNSAKiniksa Pharmaceuticals International plc$78.53-0.90%$6.1B
BLTEBelite Bio Inc$151.87-4.24%$6.1B
LGNDLigand Pharmaceuticals Incorporated$303.53-2.44%$6.1B
RYTMRhythm Pharmaceuticals Inc.$86.61-3.57%$6.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier